April 29th 2025
Jon Giles, MD, speaks to the power of personalized medicine and multidisciplinary care to enhance treatment for patients with rheumatoid arthritis (RA).
Superior Clinical Outcomes Seen in HFrEF With Early Initiation of Sacubitril/Valsartan
May 16th 2022Two periods of sacubitril/valsartan initiation were compared in a study population of patients with heart failure with reduced ejection fraction (HFrEF): less than 3 months or 3 or more months following first HFrEF diagnosis.
Read More
Superior T1D Control Seen With HCL Systems vs SAP Therapy in Older Adults
May 15th 2022Type 1 diabetes (T1D) can be especially difficult to manage in older adults, so this new multinational review compared the safety and effectiveness of a hybrid closed-loop (HCL) system and sensor-augmented pump (SAP) therapy.
Read More
Biologics Provide Opportunity to Manage Moderate to Severe Pediatric Asthma, Improve QOL
May 13th 2022Pediatric patients with asthma and their caregivers are faced with significant health and cost burdens, and biologics provide an opportunity to improve quality of life and asthma control, according to a panel of experts.
Read More
Robert Sidbury, MD, MPH, chief, division of dermatology, Seattle Children's Hospital, discussed the emergence of effective therapies for the management of atopic dermatitis and how dermatologists and other providers involved in patient care can better promote earlier use of these treatments.
Watch
PET/CT Can Assess Early Treatment Response in Newly Diagnosed MM
May 12th 2022Negative positron emission tomography/CT examinations 6 months after induction therapy in patients with newly diagnosed multiple myeloma (MM) is associated with prolonged time to next treatment and overall survival.
Read More
Physician Prices and Low-Value Services: Evidence From General Internal Medicine
This study found extensive variation in general internal medicine physician prices and that high-priced physicians provided fewer low-value services but had higher spending on these services.
Read More
Characteristics of Home-Based Care Provided by Accountable Care Organizations
May 12th 2022Accountable care organizations (ACOs) deliver a diverse array of home-based services, but many of the services are not reimbursed. ACOs may not expand these programs without strong evidence of cost savings.
Read More
Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology, discusses how community oncology practices have heightened their outreach efforts to entice patients back in for cancer screenings and the importance of thinking outside the box to overcome staffing shortages in the oncology space.
Watch
Clostridioides difficile Infection May Be Underdiagnosed in Health Care Facilities, Study Finds
May 11th 2022A study of hospitals and long-term care facilities in Louisville, Kentucky, found low rates of Clostridioides difficile testing in patients with new-onset diarrhea who are frequently infected.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Remote Monitoring Not Successful at Reducing Death, Readmission From HF
May 9th 2022In this study, investigators from Pennsylvania and New York evaluated outcomes among patients following their hospitalization for heart failure (HF) who did or did not participate in a remote monitoring program that included financial incentives for adherence.
Read More
Higher Mortality Risk Linked to ESRD Requiring LVAD Implantation in New Study
May 8th 2022A study found that patients with end stage renal/kidney disease (ESRD) who undergo left ventricular assist device (LVAD) implantation had higher 1-year mortality compared with patients with chronic kidney disease.
Read More
Cardiac Rehab Linked to Improved Mortality Among Patients With HFrEF
May 6th 2022In this study, outcomes were investigated among a cohort of patients with heart failure with reduced ejection fraction (HFrEF) who participated in a cardiac rehabilitation program post hospital discharge after they survived acute onset of HFrEF.
Read More
Machine Learning Identifies Predictors of Revision Endoscopic Sinus Surgery
May 5th 2022A machine learning approach identified age and several comorbidities, such as nasal polyps and asthma, as being associated with revision endoscopic sinus surgery among patients with chronic rhinosinusitis.
Read More
Primary Care Practice Structural Capabilities in Health Professional Shortage Areas
Nurse practitioners are increasingly meeting primary care demands in underserved areas and are more likely to deliver structural capabilities related to chronic disease management.
Read More
FDA Approves Enhertu for Use in Metastatic Breast Cancer
May 5th 2022This approval of trastuzumab deruxtecan (Enhertu) follows the March release of data from the DESTINY-Breast03 trial on the anti-HER2 monoclonal antibody, also a HER2-directed antibody-drug conjugate, which indicated superior outcomes vs trastuzumab emtansine.
Read More
Overlapping Comorbidity Risks Found in Patients With Plaque Psoriasis, Palmoplantar Pustulosis
May 5th 2022An overlapping comorbidity profile was observed among patients with plaque psoriasis and palmoplantar pustulosis, although risks of certain comorbid conditions varied between the 2 groups.
Read More
Dr Sneha Sharma Discusses the Growing Roles of Biomarker Testing, Biosimilars
May 5th 2022Biomarker testing is having growing importance to ensure that patients are started on the correct therapy for the best outcomes, said Sneha Sharma, PharmD, director, specialty clinical solutions, Magellan Rx.
Watch
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen